

2. Alternatives

The feasibility report will address an array of alternatives. Alternatives analyzed during the feasibility investigation will be a combination of one or more flood reduction measures identified during the reconnaissance phase; additional measures may be considered. These alternative measures include detention basins, hydraulic system modifications, creek widening, structural modifications, and snag clearing.

a. No Action. There will be no flood control projects implemented for west Stanislaus County.

b. Detention basin and hydraulic system modifications are proposed for Salado Creek. This alternative focuses on safely conveying flood flows from the Salado Creek foothills to the San Joaquin River.

Detention basin, creek widening, and structural modifications are proposed for Orestimba Creek. This alternative focuses on conveying flood flows from the Orestimba Creek foothills to the San Joaquin River.

3. Scoping Process

a. The project study plan provides for public scoping meeting and comment. The Corps has initiated a process of involving concerned individuals, local, state, and Federal agencies.

b. Significant issues to be analyzed in depth in the EIS/EIR include appropriate levels of the flood damage reduction, adverse effects on vegetation and wildlife resources, special-status species, esthetics, cultural resources, recreation, and cumulative impacts of related projects in the study area.

c. The Corps will consult with the State Historic Preservation Officer and the U.S. Fish and Wildlife Service to provide a Fish and Wildlife Coordination Act Report as an appendix to the EIS/EIR.

d. A 45-day public review period will be provided for individuals and agencies to review and comment on the EIS/EIR. All interested parties should respond to this notice and provide a current address if they wish to be notified of the EIS/EIR circulation.

4. A public scoping meeting will be held on March 3, 1999, from 3:00 p.m. to 8:00 p.m. at West Side Theater, 1331 Main Street, Newman, California.

5. Availability

The EIS/EIR is scheduled to be available for public review and comment late in calendar year 2000.

Dated: February 26, 1999.

Michael J. Walsh,

LTC (P), EN Commanding.

[FR Doc. 99-6622 Filed 3-17-99; 8:45 am]

BILLING CODE 3710-EZ-M

DEPARTMENT OF DEFENSE

Department of the Navy

Patents Available for Licensing

AGENCY: Department of the Navy, DOD.

ACTION: Notice.

SUMMARY: The Department of the Navy hereby gives notice of the general availability of exclusive or partially exclusive licenses under the following patents. Any license granted shall comply with 35 U.S.C. 209 and 37 CFR part 404. Applications will be evaluated utilizing the following criteria: (1) Ability to manufacture and market the technology; (2) manufacturing and marketing capability; (3) time required to bring technology to market and production rate; (4) royalties; (5) technical capabilities; (6) small business status.

Serial No. 5,880,708 entitled "Electronic Data Storage Medallion," filed March 9, 1999; Serial No. 5,814,617 entitled "Protective 17 kDa Malaria Hepatic and Erythrocytic Stage Immunogen and Gene," dated September 29, 1998; Serial No. 5,804,395 entitled "Fluorescence Polarization Assays of Enzymes and Substrates Therefore," dated September 8, 1998; Serial No. 5,795,159 entitled "Mercury Removal Method and Apparatus," dated August 18, 1998; Serial No. 5,783,441 entitled "Gene and Protein Applicable to the Preparation of Vaccines for *Rickettsia prowazekii* and *Rickettsia typhi* and the Detection of Both," dated July 21, 1998; Serial No. 5,718,883 entitled "Transgenic Animal Model for Autoimmune Diseases," dated February 17, 1998; Serial No. 5,665,559 entitled "Production of Monoclonal Antibodies to *Bacteroids Gingivalis* by Hybridoma BGII, VF9/2D," dated September 9, 1997; Serial No. 5,741,659 entitled "Rapid Microbial Protease Assay," dated April 21, 1998; Serial No. 5,630,410 entitled "Accelerated Gas Removal from Divers' Tissues Utilizing Gas Metabolizing Bacteria," dated May 20, 1997; Serial No. 5,627,521 entitled "Personal Microwave and Radio Frequency Detector," dated May 6, 1997; Serial No. 5,599,703 entitled "In Vitro Amplification/Expansion of CD34+ Stem and Progenitor Cells," dated February 4, 1997; Serial No. 5,599,543

entitled "Immunogenic Four Amino Acid Epitope Against *Plasmodium vivax*," dated February 4, 1997; Serial No. 5,596,090 entitled "Antisense Oligonucleotides Directed Against Human VCAM-I RNA," dated January 21, 1997; Serial No. 5,585,479 entitled "Antisense Oligonucleotides Directed Against Human ELAM-I RNA," dated December 17, 1996; Serial No. 5,580,969 entitled "Antisense Oligonucleotides Directed Against Human ICAM-I RNA," dated December 3, 1996; Serial No. 5,546,241 entitled "Projector Slides for Night Vision Training," dated August 13, 1996; Serial No. 5,514,553 entitled "Production of Monoclonal Antibodies to *Treponema denticola* by Hybridoma TDII,IAA11," dated May 7, 1996; Serial No. 5,494,795 entitled "Specific Oligonucleotide Primers for Detection of Pathogenic *Campylobacter* Bacteria by Polymerase Chain Reaction," dated February 27, 1996; Serial No. 5,486,821 entitled "Artificial Horizon Altitude Warning System," dated January 23, 1996; Serial No. 5,485,834 entitled "Manually Tunable, Closed-Circuit Underwater Breathing Apparatus," dated January 23, 1996; Serial No. 5,473,472 entitled "Night Vision Goggle Focusing Aid," dated December 5, 1995; Serial No. 5,421,340 entitled "Compact, Portable Critical Care Unit For Hyperbaric And Recompression Chambers," dated June 6, 1995; Serial No. 5,363,298 entitled "Controlled Risk Decompression Meter," dated November 8, 1994; Serial No. 5,315,988 entitled "Reactive, Closed-Circuit Underwater Breathing Apparatus," dated May 31, 1994; Serial No. 5,312,322 "Three Point Extension Splint to Treat Flexion Contractures About Limb Synovial Hinge Joints," dated May 17, 1994; Serial No. 5,299,567 entitled "Minimal Elastance, Closed-Circuit Underwater Breathing Apparatus," dated April 5, 1994; Serial No. 5,255,117 entitled "Advanced Eye or Sensor Protection and High Speed Variable Optical Attenuation System," dated October 19, 1993; Serial No. 5,223,866 Small, Simple and Cost-Effective Scheiner-Principle Optometer with Computer Interface for Automated Assessment," dated June 29, 1993; Serial No. 5,200,312 entitled "Membrane Based Dot Immunoassay and Method of Use," dated April 6, 1993; Serial No. 5,198,535 entitled "Protective Malaria Sporozoite Surface Protein Immunogen and Gene," dated March 30, 1993; Serial No. 5,162,990 entitled "System and Method for Quantifying Macrophage Phagocytosis by Computer Image Analysis," dated November 10, 1992; Serial No. 5,095,093 Protective Amino

Acid Epitope Against *Plasmodium vivax* Malaria," dated March 10, 1992; Serial No. 5,093,235 entitled "Immuno-Dye Reagent and Assay for Detection of Endotoxin," dated March 3, 1992; Serial No. 5,039,493 entitled "Positive Pressure Blotting Apparatus with Hydrophobic Filter Means," dated August 13, 1991; Serial No. 4,997,269 entitled "Scheiner-Principle Pocket Optometer for Self Evaluation and Bio-Feedback Accommodation Training," dated March 5, 1991; Serial No. 4,959,304 entitled "Production of Monoclonal Antibodies to *Treponema denticola* by Hybridoma DIII.IIIB2," dated September 25, 1990; Serial No. 4,943,151 entitled "Scheiner-Principle Vernier Optometer," dated July 24, 1990;

DATES: Applications for an exclusive or partially exclusive license may be submitted at any time from the date of this notice.

ADDRESSES: Naval Medical Research Center, 8901 Wisconsin Ave, Bethesda, MD 20889-5607.

FOR FURTHER INFORMATION CONTACT: CDR Charles J. Schlagel, Marketing Director, Naval Medical Research Center, 8901 Wisconsin Ave, Bethesda, MD 20889-5607. Telephone (301) 295-5658.

Pamela A. Holden,

Lieutenant Commander, Judge Advocate General Corps, U.S. Navy, Federal Register Liaison Officer.

[FR Doc. 99-6605 Filed 3-17-99; 8:45am]

BILLING CODE 3810-FF-P

DEPARTMENT OF DEFENSE

Department of the Navy

Government-Owned Inventions Available for Licensing

AGENCY: Department of the Navy, DOD.

ACTION: Notice.

SUMMARY: The Department of the Navy hereby gives notice of the general availability of exclusive or partially exclusive licenses under the following pending patents. Any license granted shall comply with 35 USC 209 and 37 CFR Part 404. Applications will be evaluated utilizing the following criteria: (1) Ability to manufacture and market the technology; (2) manufacturing and marketing capability; (3) time required to bring technology to market and production rate; (4) royalties; (5) technical capabilities; (6) Small business status.

Serial No. 60/101001 entitled "Intestinal Hydrogen Removal Using Hydrogen-metabolizing Microbes," dated September 18,

1998; Serial No. 08/595688 entitled "Rapid Immunoassay for Periodontopathic Bacteria," dated February 2, 1996; Serial No. 09/044214 entitled "Rapid Immunoassay to Detect Infection With Mycobacterium tuberculosis," dated November 27, 1995; Serial No. 08/766203 entitled "Rapid Immunoassay for Cariogenic Bacteria," dated December 12, 1996; Serial No. 07/583170 entitled "Rapid Microbial Protease Assay," dated January 4, 1996; Serial No. 08/556391 entitled "Method and System for Removing Mercury From Dental Waste Water," dated December 1, 1995; Serial No. 08/048042 entitled "Transgenic Mouse Expressing T Lymphocyte Activating Molecule, B7, on Pancreatic Beta Cells," dated February 17, 1994; Serial No. 82,004 entitled "Composition and Method to Prevent Graft Rejection and Other Counter Adaptive T Lymphocyte Mediated Immune Responses," dated June 11, 1997; Serial No. 60/077104 entitled "PKC-mediated Dendritic Cell Differentiation Pathway," dated March 6, 1998; Serial No. 60/049389 entitled "Blocking the Rejection of an Allograft Using the Combination of CD28 Pathway Blocker (CTLAY-Ig) and Anti-CD40L, in Primates," dated June 11, 1997; Serial No. 08/587609 entitled "Murine Hybridoma and Antibody Binding to CD28 Receptor Secreted by the Hybridoma and Method of Using the Antibody," dated January 17, 1996; Serial No. 82011 entitled "Human Brain Vascular Endothelial Cell Growth Medium and Method for Expansion of Primitive CD34+, CD38-Bone Marrow Stem Cells," dated December 4, 1998; Serial No. 08/772,225 entitled "Use of Oral Interleukin-6 as Therapy for Hemorrhagic Shock," dated December 20, 1996; Serial No. 08/671,056 entitled "Recombinant Fusion Protein Subunit Vaccine Against Dengue Virus Infection," dated June 27, 1996; Serial No. 08/053450 Method of Use of Protective Malaria Sporozoite Surface Protein Immunogen and Gene," dated September 19, 1997; Serial No. 08/176024 entitled "Murine Monoclonal Antibodies Protective Against P. vivax Malaria," dated September 20, 1996; Serial No. 08/234027 entitled "Method of Using Interleukin-12 to Provide Protection Against Infection with Malaria," dated August 20, 1996; Serial No. 08/000906 entitled "Pharmaceutical Composition of Esherichia coli Heat-labile Enterotoxin Adjuvant and Methods of Use," dated January 6, 1993; Serial No. 09/159568 entitled "A Method to Preserve Bacteria in a Fully Dehydrated State Without Special Equipment," dated September 24, 1998; Serial No. 08/027254 entitled "Naked DNA Vaccine Against Hepatitis E Virus Infection," dated March 18, 1998; Serial No. 78,997 entitled "CPG Immunostimulatory Motifs For the Prophylaxis of an Treatment for Malaria (P. falciparum, P. vivax, P. ovale and P. malarie)," dated December 15, 1998; Serial No. 79,092 entitled "Molecular Analysis of Attenuated Strains of Dengue Virus After Serial Passage in Primary Dog Kidney Cells," dated August 21, 1998; Serial No. 60/101002 entitled "The Increase in Seroreactivity of Surface Protein Antigen of typhus Rickettsia Due to Methylation," dated September 18, 1998; Serial No. 08/869423 entitled "PD2ME

and p1012D2ME, Dengue-2 Virus DNA Vaccine," dated June 4, 1997; Serial No. 60/108114 entitled "Use of Recombinant Flagellin as Campylobacter Vaccine," dated July 15, 1997; Serial No. 60/068732 entitled "Expression and Refolding of the Major Outer Membrane Protein of Orientia tsutsugamushi and Its Use in Enzyme-linked Immunosorbant Assays," dated December 24, 1997; Serial No. 09/163,339 entitled "Diagnostic Monoclonal Antibody for Vibrio cholerae 0139," dated September 29, 1997; Serial No. 60/060,558 entitled "Diagnostic Monoclonal Antibody for Vibrio cholerae 01," dated September 17, 1996; Serial No. 60/082,947 entitled "Method and Process for Establishment of Stage Specific Expression and Characterization of Proteins Based on Microbial or Human Genomic Sequence Data," dated April 24, 1998; Serial No. 60/107131 entitled "Chromosome 2 Sequence of the Human Malaria Parasite Plasmodium falciparum and Proteins of said Chromosome Useful in Anti-Malarial Vaccines and Diagnostic Reagents," dated October 30, 1998; Serial No. 08/155888 entitled "Polynucleotide Vaccine Protective Against Malaria, Methods of Protection and Vector for Delivering Polynucleotide Vaccines," dated November 23, 1993; Serial No. 8/917543 entitled "Rapid Detection and Quantification of Pathogens Using Filter Monitor Technology and Colony Lift Immunoassay," dated August 26, 1997; Serial No. 60/069761 entitled "Prevention or Reversal of Sensorineural Hearing Loss (SNHL) Through Biologic Mechanisms," dated July 31, 1998; and Serial No. 08/660000 Ultra-Low Temperature Neck Bonding Process," dated May 27, 1997.

DATES: Applications for an exclusive or partially exclusive license may be submitted at any time from the date of this notice.

ADDRESSES: Naval Medical Research Center, 8901 Wisconsin Ave, Bethesda, MD 20889-5607.

FOR FURTHER INFORMATION CONTACT: CDR Charles J. Schlagel, Marketing Director, Naval Medical Research Center, 8901 Wisconsin Ave, Bethesda, MD 20889-5607. Telephone (301) 295-5658.

Pamela A. Holden,

Lieutenant Commander, Judge Advocate General Corps, U.S. Navy, Federal Register Liaison Officer.

[FR Doc. 99-6606 Filed 3-17-99; 8:45am]

BILLING CODE 3810-FF-P

DEPARTMENT OF EDUCATION

Notice of Proposed Information Collection Requests

AGENCY: Department of Education.

ACTION: Notice of proposed information collection requests.

SUMMARY: The Acting Leader, Information Management Group, Office of the Chief Information Officer, invites